Navigation Links
Merrimack Pharmaceuticals Recognized for Innovative Talent Management in HR Executive Magazine's ‘Best HR Ideas for 2010' Issue

Monthly dialogues replace annual reviews to give employees more ‘real time’ feedback. Employee development is a priority at Merrimack, which has hired 50 people since October 2009 and is a recipient of a $1.5 million Massachusetts Life Sciences Center tax incentive award for job creation.

Cambridge, Mass (PRWEB) March 24, 2010 -- Merrimack Pharmaceuticals was one of 18 winners out of more than 100 entries in Human Resources magazine’s second annual competition for the most noteworthy HR ideas. Awards were in four categories: Benefits, HR Technology, Talent Management and Training & Development.

Merrimack was recognized in the Talent Management category for the company’s decision last year to replace its semi-annual review process with 12 monthly employee dialogue sessions. “Talking monthly helps ensure that managers are actively involved in their employees’ development and creates alignment around team and company objectives,”    said Andy Porter, senior director of Human Resources, at Merrimack. “As Merrimack continues to grow, it’s critically important that we have a strong foundation of manager-employee feedback in place.” The dialogues include: goal check-in, job competencies and development, one actionable item the employee can improve, and types of support the manager can provide.

About Merrimack
Merrimack is a biopharmaceutical company dedicated to the discovery and development of novel medicines for the treatment of cancer and inflammation. The Company is advancing a robust pipeline of engineered therapeutics paired with molecular diagnostics. Merrimack’s first two oncology candidates, MM-121, partnered with sanofi-aventis, and MM-111, are in Phase 1 clinical testing with multiple pre-clinical development and research stage programs in the pipeline. MM-121 and MM-111 are investigational drugs and have not been approved by the U.S. Food and Drug Administration or any international regulatory agency. The Company’s proprietary Network Biology discovery platform, developed with the help of leading scientists from MIT and Harvard, integrates the fields of engineering, biology, and computing to enable mechanism-based, model driven discovery and development of both therapeutics and diagnostics. Merrimack is a privately-held company based in Cambridge, Massachusetts. For additional information, please visit


Read the full story at

Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved  

Related biology technology :

1. Merrimack Pharmaceuticals Initiates Enrollment in Phase 1/2 Combination Study of MM-121 and Tarceva in Patients with Non-Small Cell Lung Cancer
2. Merrimack Pharmaceuticals Acquires Hermes Biosciences, Inc.
3. Merrimack Pharmaceuticals Names Clet Niyikiza, Ph.D. Senior Vice President, Development
4. Merrimack Pharmaceuticals Promotes Ulrik B. Nielsen, Ph.D. to Chief Scientific Officer and Edward J. Stewart to Senior Vice President of Business Development
5. Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Study of MM-121, an ErbB3 Antagonist
6. Merrimack Pharmaceuticals Raises $60 Million in Private Financing
7. Merrimack Pharmaceuticals Announces the Addition of Robert Gay to its Board of Directors
8. Shire Receives INTUNIV (TM) Paragraph IV Notice Letter From Teva Pharmaceuticals
9. OncoGenex Pharmaceuticals to Webcast Discussion of Financial Results for Fourth Quarter and Fiscal Year 2009
10. Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009
11. OncoGenex Pharmaceuticals to Present at RBC Capital Markets Healthcare Conference
Post Your Comments:
Related Image:
Merrimack Pharmaceuticals Recognized for Innovative Talent Management in HR Executive Magazine's ‘Best HR Ideas for 2010' Issue
(Date:10/10/2017)... Los Angeles, CA (PRWEB) , ... ... ... Pharmaceuticals, Inc., a development-stage cancer-focused pharmaceutical company advancing targeted antibody-drug conjugate (ADC) ... all uses of targeted HPLN (Hybrid Polymerized Liposomal Nanoparticle), a technology developed ...
(Date:10/10/2017)... SomaGenics announced the receipt of a Phase ... (Single Cell), expected to be the first commercially available ... from single cells using NGS methods. The NIH,s recent ... development of approaches to analyze the heterogeneity of cell ... for measuring levels of mRNAs in individual cells have ...
(Date:10/9/2017)... ... ... The award-winning American Farmer television series will feature 3 Bar Biologics in ... 8:30aET on RFD-TV. , With global population estimates nearing ten billion people by ... feed a growing nation. At the same time, many of our valuable resources are ...
(Date:10/7/2017)... Phoenix, Arizona (PRWEB) , ... ... ... than 15 years’ experience providing advanced instruments and applications consulting for microscopy ... the in-house expertise in application consulting, Nanoscience Analytical offers a broad range ...
Breaking Biology Technology:
(Date:4/4/2017)... --  EyeLock LLC , a leader of iris-based identity ... and Trademark Office (USPTO) has issued U.S. Patent No. ... iris image with a face image acquired in sequence ... th issued patent. "The issuance ... multi-modal biometric capabilities that have recently come to market ...
(Date:3/30/2017)... 2017 Trends, opportunities and forecast in this ... technology (fingerprint, AFIS, iris recognition, facial recognition, hand geometry, ... end use industry (government and law enforcement, commercial and ... and others), and by region ( North America ... Asia Pacific , and the Rest of the ...
(Date:3/24/2017)... The Controller General of Immigration from Maldives Mr. Mohamed ... received the prestigious international IAIR Award for the most innovative high security ... ... Maldives Immigration Controller General, ... picture on the right) have received the IAIR award for the "Most ...
Breaking Biology News(10 mins):